학술논문
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
Document Type
Article
Author
Iqbal, Madiha; Jagadeesh, Deepa; Chavez, Julio; Khurana, Arushi; Rosenthal, Allison; Craver, Emily; Epperla, Narendranath; Li, Zhuo; Isufi, Iris; Awan, Farrukh T.; Dholaria, Bhagirathbhai R.; Maakaron, Joseph E.; Sandoval-Sus, Jose D.; Mishra, Rahul; Saha, Aditi; Annunzio, Kaitlin; Bhaskar, Shakthi T.; Sumransub, Nuttavut; Fijalka, Andrew; Ivanov, Stanislav A.; Lin, Yi; Kharfan-Dabaja, Mohamed A.
Source
Bone Marrow Transplantation; February 2024, Vol. 59 Issue: 2 p211-216, 6p
Subject
Language
ISSN
02683369; 14765365
Abstract
Outcomes are poor for patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) post chimeric antigen receptor T-cell (CAR-T) therapy. Two CD19-directed therapies, tafasitamab- cxix plus lenalidomide (tafa-len) and loncastuximab tesirine (loncaT) are approved in R/R LBCL. The efficacy of these CD19 directed therapies in patients who relapse after CD19 directed CAR-T (CD19-CART) therapy is not well understood. We conducted a multi-center study of patients with R/R LBCL that received either tafa-len or loncaT at any timepoint for R/R disease after CD19-CART therapy. Fifty-three patients were included in this study with the median follow up of 56 (9.1–199) weeks from CAR-T infusion. Median number of systemic therapies pre–CAR-T therapy was 3 (range: 1–6); axicabtagene ciloleucel was the most utilized CAR-T product (n= 32,60%). Median time from CAR-T therapy to tafa-len or loncaT was 7.3 (1.2–38.2) months with median number of lines of therapy between CAR-T therapy and these regimens of 1 (0–5). Combined overall response rate and complete response rates were 27% and 10%, respectively. Median duration of response was 13.3 (2.1–56.7) weeks. In this real-world study, the use of currently approved CD19-directed therapies to treat R/R LBCL after CD19-CAR-T therapy showed limited clinical activity and duration of responses.